Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007494
Filing Date
2025-05-13
Accepted
2025-05-13 07:45:36
Documents
108
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q xoma-20250331x10q.htm   iXBRL 10-Q 2401099
2 EX-31.1 xoma-20250331xex31d1.htm EX-31.1 10492
3 EX-31.2 xoma-20250331xex31d2.htm EX-31.2 10521
4 EX-32.1 xoma-20250331xex32d1.htm EX-32.1 8553
  Complete submission text file 0001558370-25-007494.txt   12409591

Data Files

Seq Description Document Type Size
5 EX-101.SCH xoma-20250331.xsd EX-101.SCH 102716
6 EX-101.CAL xoma-20250331_cal.xml EX-101.CAL 83333
7 EX-101.DEF xoma-20250331_def.xml EX-101.DEF 504225
8 EX-101.LAB xoma-20250331_lab.xml EX-101.LAB 759735
9 EX-101.PRE xoma-20250331_pre.xml EX-101.PRE 700817
111 EXTRACTED XBRL INSTANCE DOCUMENT xoma-20250331x10q_htm.xml XML 2215181
Mailing Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608
Business Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239
XOMA Royalty Corp (Filer) CIK: 0000791908 (see all company filings)

EIN.: 522154066 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39801 | Film No.: 25937181
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)